{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:42:15Z","timestamp":1761972135035,"version":"build-2065373602"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,11,1]]},"DOI":"10.2169\/internalmedicine.5141-24","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T18:07:25Z","timestamp":1745863645000},"page":"3107-3110","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Combined Dabrafenib and Trametinib Therapy in &lt;i&gt;BRAFV600E&lt;\/i&gt; Mutant Intrahepatic Cholangiocarcinoma with a Neurofibromatosis Type 2 Mutation"],"prefix":"10.2169","volume":"64","author":[{"given":"Jumpei","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seira","family":"Owaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Emi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sako","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riku","family":"Ino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyoe","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHO Nagoya Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Banales JM, Marin JJ, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17: 557-588, 2020.","DOI":"10.1038\/s41575-020-0310-z"},{"key":"2","unstructured":"2. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13: 261-280, 2016."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res 22: 291-300, 2016.","DOI":"10.1158\/1078-0432.CCR-14-3296"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol 107064, 2023.","DOI":"10.1016\/j.ejso.2023.107064"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73: 198-222, 2023.","DOI":"10.3322\/caac.21759"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet 397: 428-444, 2021.","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Oh DY, Ruth He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1: EVIDoa2200015, 2022.","DOI":"10.1056\/EVIDoa2200015"},{"key":"8","unstructured":"8. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401: 1853-1865, 2023."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Subbiah V, Lassen U, \u00c9lez E, et al. Dabrafenib plus trametinib in patients with <i>BRAF<\/i><sup>V600E<\/sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 21: 1234-1243, 2020.","DOI":"10.1016\/S1470-2045(20)30321-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cannon TL, Rothe M, Mangat PK, et al. Pertuzumab plus trastuzumab in patients with biliary tract cancer with <i>ERBB2\/3<\/i> alterations: results from the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol 42: 3228-3237, 2024.","DOI":"10.1200\/JCO.23.02078"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with <i>BRAF<\/i> V600 mutations. N Engl J Med 373: 726-736, 2015.","DOI":"10.1056\/NEJMoa1502309"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Salama AK, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with <i>BRAF<\/i><sup>V600E<\/sup> mutations: results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol 38: 3895-3904, 2020.","DOI":"10.1200\/JCO.20.00762"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in <i>BRAF<\/i>V600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 29: 1103-1112, 2023.","DOI":"10.1038\/s41591-023-02321-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Durham BH, Getta B, Dietrich S, et al. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood 130: 1644-1648, 2017.","DOI":"10.1182\/blood-2017-01-765107"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343: 84-87, 2014.","DOI":"10.1126\/science.1247005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Schulz A, Raetz J, Karitzky PC, et al. Head-to-head comparison of BRAF\/MEK inhibitor combinations proposes superiority of encorafenib plus trametinib in melanoma. Cancers (Basel) 14: 4930, 2022.","DOI":"10.3390\/cancers14194930"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/21\/64_5141-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:26:35Z","timestamp":1761967595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/21\/64_5141-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":16,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5141-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"article-number":"5141-24"}}